AU2013239383B2 - Methods for detection of anti-cytomegalovirus neutralizing antibodies - Google Patents

Methods for detection of anti-cytomegalovirus neutralizing antibodies Download PDF

Info

Publication number
AU2013239383B2
AU2013239383B2 AU2013239383A AU2013239383A AU2013239383B2 AU 2013239383 B2 AU2013239383 B2 AU 2013239383B2 AU 2013239383 A AU2013239383 A AU 2013239383A AU 2013239383 A AU2013239383 A AU 2013239383A AU 2013239383 B2 AU2013239383 B2 AU 2013239383B2
Authority
AU
Australia
Prior art keywords
hcmv
infection
cells
virus
fluorescence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013239383A
Other languages
English (en)
Other versions
AU2013239383A1 (en
Inventor
David E. Anderson
Jasminka BOZIC
Barthelemy ONTSOUKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Variation Biotechnologies Inc
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Publication of AU2013239383A1 publication Critical patent/AU2013239383A1/en
Application granted granted Critical
Publication of AU2013239383B2 publication Critical patent/AU2013239383B2/en
Assigned to VARIATION BIOTECHNOLOGIES INC. reassignment VARIATION BIOTECHNOLOGIES INC. Amend patent request/document other than specification (104) Assignors: VARIATION BIOTECHNOLOGIES, INC.
Priority to AU2018271276A priority Critical patent/AU2018271276B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2013239383A 2012-03-27 2013-03-27 Methods for detection of anti-cytomegalovirus neutralizing antibodies Ceased AU2013239383B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018271276A AU2018271276B2 (en) 2012-03-27 2018-11-27 Methods for detection of anti-cytomegalovirus neutralizing antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616204P 2012-03-27 2012-03-27
US61/616,204 2012-03-27
PCT/IB2013/001021 WO2013144722A2 (en) 2012-03-27 2013-03-27 Methods for detection of anti-cytomegalovirus neutralizing antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018271276A Division AU2018271276B2 (en) 2012-03-27 2018-11-27 Methods for detection of anti-cytomegalovirus neutralizing antibodies

Publications (2)

Publication Number Publication Date
AU2013239383A1 AU2013239383A1 (en) 2014-10-16
AU2013239383B2 true AU2013239383B2 (en) 2018-10-04

Family

ID=49261346

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013239383A Ceased AU2013239383B2 (en) 2012-03-27 2013-03-27 Methods for detection of anti-cytomegalovirus neutralizing antibodies
AU2018271276A Ceased AU2018271276B2 (en) 2012-03-27 2018-11-27 Methods for detection of anti-cytomegalovirus neutralizing antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018271276A Ceased AU2018271276B2 (en) 2012-03-27 2018-11-27 Methods for detection of anti-cytomegalovirus neutralizing antibodies

Country Status (11)

Country Link
US (2) US10006096B2 (enExample)
EP (2) EP2831285B1 (enExample)
JP (1) JP6265344B2 (enExample)
KR (2) KR102146340B1 (enExample)
CN (2) CN119716047A (enExample)
AU (2) AU2013239383B2 (enExample)
BR (1) BR112014023913B1 (enExample)
CA (1) CA2867789C (enExample)
MX (1) MX354822B (enExample)
RU (1) RU2660712C2 (enExample)
WO (1) WO2013144722A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102146340B1 (ko) * 2012-03-27 2020-08-24 배리에이션 바이오테크놀로지스 아이엔씨. 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
JP6850483B2 (ja) * 2018-03-06 2021-03-31 株式会社ＣｅＳＰＩＡ Ｃｅｌｌ−ｂａｓｅｄ ａｓｓａｙ法に基づいたハイスループット抗体検出方法
WO2019232453A1 (en) * 2018-06-01 2019-12-05 Gravid Therapies, Inc. Methods, kits, and products for detection of cytomegalovirus infection
WO2020036811A1 (en) * 2018-08-14 2020-02-20 Merck Sharp & Dohme Corp. A virus neutralization assay utilizing imaging cytometry
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111474339A (zh) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 一种利用荧光标记痘病毒颗粒的方法及其应用
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CN112362649B (zh) * 2020-11-09 2024-07-12 长春金赛药业有限责任公司 一种rhGH中和抗体的检测方法
CN112945919B (zh) * 2021-01-29 2023-04-28 上海睿钰生物科技有限公司 一种病毒中和抗体的检测方法、系统及其应用
CN114859046B (zh) * 2021-04-30 2025-11-28 中国人民解放军军事科学院军事医学研究院 含高效价抗hcmv中和抗体原料血浆的筛选方法和抗hcmv中和抗体效价的检测方法
US20250157651A1 (en) * 2022-01-19 2025-05-15 Trustees Of Dartmouth College Systems and methods for deterring viral transmission using neural networks
WO2023154857A2 (en) * 2022-02-11 2023-08-17 Trustees Of Dartmouth College Systems and methods for identifying and treating primary and latent infections and/or determining time since infection
CN119192349A (zh) * 2024-07-18 2024-12-27 北京市延庆区疾病预防控制中心 用于检测黄连素抗性病毒的试剂及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025095A1 (en) * 2006-09-01 2008-03-06 Csl Limited Method of eliciting or inducing an immune response

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
US5248768A (en) * 1986-11-24 1993-09-28 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus
JPH06222062A (ja) 1993-01-22 1994-08-12 Teijin Ltd ウイルス感染価および中和抗体価の測定法
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
US6569616B1 (en) * 1999-07-29 2003-05-27 Wisconsin Alumni Research Foundation Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
US6849409B2 (en) * 2000-10-16 2005-02-01 Axxima Pharmaceuticals Ag Cellular kinases involved in Cytomegalovirus infection and their inhibition
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
CN1686541A (zh) * 2005-04-11 2005-10-26 王明丽 人巨细胞病毒pp65蛋白质疫苗的制备方法
US9439960B2 (en) * 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
AU2008359583B2 (en) * 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
US20100267583A1 (en) 2009-04-15 2010-10-21 Variation Biotechnologies Inc. Method and kit for detection of hepatitis a virus neutralizing antibodies
US9145577B2 (en) 2010-08-10 2015-09-29 The Research Foundation Of State University Of New York Lipoprotein lipase assay
JP6232544B2 (ja) 2011-11-11 2017-11-22 ヴァリエーション バイオテクノロジーズ インコーポレイテッド サイトメガロウイルスの治療のための組成物及び方法
KR102146340B1 (ko) * 2012-03-27 2020-08-24 배리에이션 바이오테크놀로지스 아이엔씨. 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025095A1 (en) * 2006-09-01 2008-03-06 Csl Limited Method of eliciting or inducing an immune response

Also Published As

Publication number Publication date
CN119716047A (zh) 2025-03-28
MX2014011504A (es) 2015-03-13
WO2013144722A3 (en) 2013-11-28
EP3613431A1 (en) 2020-02-26
US10006096B2 (en) 2018-06-26
EP3613431B1 (en) 2023-01-11
EP2831285A4 (en) 2015-10-28
JP2015518140A (ja) 2015-06-25
US10161010B2 (en) 2018-12-25
JP6265344B2 (ja) 2018-01-24
KR20140146630A (ko) 2014-12-26
BR112014023913B1 (pt) 2022-08-09
US20180274044A1 (en) 2018-09-27
AU2018271276A1 (en) 2018-12-20
CA2867789A1 (en) 2013-10-03
CA2867789C (en) 2022-06-14
RU2014142815A (ru) 2016-05-20
KR102146340B1 (ko) 2020-08-24
EP2831285A2 (en) 2015-02-04
RU2660712C2 (ru) 2018-07-09
KR102314245B1 (ko) 2021-10-20
CN104321444A (zh) 2015-01-28
AU2018271276B2 (en) 2021-06-03
US20150044668A1 (en) 2015-02-12
EP2831285B1 (en) 2019-10-30
BR112014023913A2 (enExample) 2017-06-20
AU2013239383A1 (en) 2014-10-16
KR20200095575A (ko) 2020-08-10
WO2013144722A2 (en) 2013-10-03
MX354822B (es) 2018-03-21

Similar Documents

Publication Publication Date Title
US10161010B2 (en) Methods for detection of anti-cytomegalovirus neutralizing antibodies
Speck et al. Epstein–Barr virus entry into cells
Ye et al. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals
Parker et al. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox–an animal model of smallpox
EP1799255A1 (en) Recombinant human cytomegalovirus and vaccines comprising heterologous antigens
BR112014011229B1 (pt) Partículas vírus-like (vlp), composição farmacêutica compreendendo a referida partícula, método de produção e uso da mesma
ES2392670T3 (es) Vectores recombinantes basados en el virus modificado de Ancara (MVA) como vacunas preventivas y terapéuticas contra el sida
EP4416274A2 (en) Pharmaceutical compositions for delivery of viral antigens and related methods
Hayes et al. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults
JP2006514549A (ja) Ｉｌ−１５を発現する組換えワクチンウイルスおよびその使用方法
Antonis et al. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge
US20190224303A1 (en) Vaccine
Haberthur et al. Genome-wide analysis of T cell responses during acute and latent simian varicella virus infections in rhesus macaques
Hukkanen et al. Simian varicella virus in pigtailed macaques (Macaca nemestrina): clinical, pathologic, and virologic features
Morinet et al. Chronic fatigue syndrome and viral infections
Pozzi et al. Charge and pH effect on the early events of Epstein-Barr virus fusion with lymphoblastoid cells (Raji)
Breuer et al. Varicella Zoster
ES2401904A2 (es) Vectores recombinantes basados en el virus modificado de ankara (mva), con deleción en el gen c6l, como vacunas contra el vih/sida y otras enfermedades.
O'Connor Structural and Proteomic Analyses of the Gammaherpesviruses KSHV and RRV
Lee Interaction of HSV-1 and PRV with cell surface components during infectious entry
Kumar et al. P. 354 HBV specific acyclic pyrimidine nucleosides: synthesis and anti-HBV activity of 5-and/or 6-substituted analogs of 1-[(2-hydroxyethoxy) methyl] uracils
Agrawal et al. P. 355 Dendritic cells expressing hepatitis C virus (HCV) derived antigens NS3 or Core: phenotype, antigen presentation and T cell stimulation
Kramski Infections of common marmosets with calpox virus

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: VARIATION BIOTECHNOLOGIES INC.

Free format text: FORMER NAME(S): VARIATION BIOTECHNOLOGIES, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired